Prostate Cancer - Results from #140

Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. March 6, 2023

Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial. March 6, 2023

Long-term Health-related Quality of Life in Patients on Active Surveillance for Prostate Cancer: A Systematic Review. March 6, 2023

Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review. March 6, 2023

Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. March 6, 2023

p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up. March 6, 2023

Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer. March 6, 2023

Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. March 6, 2023

HER2 as a potential therapeutic target on quiescent prostate cancer cells. March 6, 2023

Remodeling oncogenic transcriptomes by small molecules targeting NONO. March 6, 2023

Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers. March 5, 2023

Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. March 3, 2023

Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging. March 3, 2023

Multi-timepoint imaging with PSMA-targeted [18F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging. March 3, 2023

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy. March 3, 2023

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. March 3, 2023

Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre. March 2, 2023

A Comparison Between the Rates of Radiation Oncologist and Urologist Consultations in Men Diagnosed With Prostate Cancer in Northern Ontario, Canada. March 2, 2023

Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy. March 2, 2023

Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen -deprivation therapy: A multicenter retrospective analysis. March 2, 2023

Page 8 of 1290